6 weekly. At the last visit, 5 months after commencing infliximab treatment, the disease appears to be quiet (Figure, E and F) . Snellen visual acuity is currently 6/60 OD, improving to 6/18 OD with a scleral contact lens. Unfortunately, the patient has no vision in the left eye due to the uncontrolled glaucoma. Infliximab infusions are currently being continued at decreasing intervals.
Comment. This case demonstrates how difficult Mooren ulceration can be to treat, given both the delay in onset of action and adverse effects of conventional immunosuppressive therapy. The pathogenesis of Mooren ulceration is uncertain but may involve an immune response to a corneal stromal protein (corneal antigen), which is identical to calgranulin C released by neutrophils during the host defense response to helminths.
1 Infiltration of lymphocytes, macrophages, and Langerhans cells has been observed in the conjunctiva adjacent to Mooren ulceration. 2 Tumor necrosis factor ␣ is an important cytokine in the establishment and maintenance of inflammation in many autoimmune diseases, and the success of tumor necrosis factor ␣ antagonists in immune-mediated rheumatic diseases has led to its off-label use in ocular inflammatory disease. 3 Apart from inhibition of tumor necrosis factor ␣, infliximab also appears to induce regulatory T cells in rheumatoid arthritis 4 and to induce T-cell apoptosis in Crohn disease, 5 both of which might be relevant in ocular inflammation.
To our knowledge, effective treatment with tumor necrosis factor ␣ antagonists has not previously been described in Mooren ulceration. This article shows that addition of infliximab may be useful when rapid control of inflammation is desirable and/or when conventional immunosuppressive therapy is not tolerated or effective.
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